# Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

> **NCT03614923** · PHASE2 · COMPLETED · sponsor: **AnaptysBio, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Chronic Rhinosinusitis

## Interventions

- **BIOLOGICAL:** Etokimab
- **BIOLOGICAL:** Placebo
- **DRUG:** Mometasone Furoate Nasal Spray

## Key facts

- **NCT ID:** NCT03614923
- **Lead sponsor:** AnaptysBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-29
- **Primary completion:** 2020-09-02
- **Final completion:** 2020-10-26
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614923, "Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03614923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*